Stereotactic Surgery Devices Market Size, Share, and COVID-19 Impact Analysis, By Equipment Type (Gama Knife, Linear Accelerator (LINAC), and Proton Beam), By Application (Brain Tumor, Epilepsy, Trigeminal Neuralgia, Arteriovenous Malformations, and Others), By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), and Regional Forecast, 2024-2032

Stereotactic surgery is a form of minimal invasive surgery that makes use of a three-dimensional image (MRI) to locate small targets inside the body and perform some form of action such as ablation (removal), biopsy, lesion, injection, stimulation, implantation, radiosurgery (SRS), and others. In traditional stereotactic surgery, a lightweight frame attached to the head frame can be adjusted to the three-dimensional coordinates of the target, and the surgeon can accurately approach the target. A common example would be a stereotactic brain biopsy.

Deep tumors within the brain may be difficult and dangerous to approach by an open operation. However, a stereotactic biopsy apparatus can perform deep brain surgery accurately to treat movement or neurological disorders. This accuracy in treatment is one of the driving factors for this device.

• In May 2020, an article was published by the National Institute of Health about the efficacy and safety of stereotactic radiosurgery for brainstem metastases. It concluded that the patients treated with stereotactic radiosurgery (SRS) for brainstem metastasis (BSM) rarely died from its progression and often experienced symptomatic improvement. Such studies supporting the safety and efficacy of SRS for BSM in the context of acute morbidity or death from BSM growth increase its preference compared to other procedures. This preference will drive the demand for these devices in the market.

The success rate of these devices can be its driving factor because many institutes are incorporating these devices in their curriculum, and several government and non-government organizations support this change.

• In March 2021, Augmedics, a medical technology manufacturer, raised USD 36 million to support stereotactic surgical navigation, showing the contribution and willingness towards developing stereotactic devices.

However, the downside to these devices would be their high cost as they use sophisticated technology and involve more than one complex procedure to give an output. Furthermore, the manufacturing cost of these devices is high, limiting their demand and leading to slower market growth.

Impact of COVID-19 on the Stereotactic Surgery Devices Market

The COVID-19 pandemic negatively affected the global stereotactic surgery devices market as all aspects of the healthcare ecosystem were overwhelmed by COVID-19 cases. Many countries held back or delayed surgeries, including stereotactic radiosurgery (SRS), during this period because of the risk of getting infected by COVID-19. The impact was also observed on the revenue of key companies operating in the market.

• For instance, Elekta, one of the prominent manufacturers of stereotactic devices, witnessed a decline in its revenue by USD 82.8 million during the 2020-2021 period due to disruptions in the supply chain impacted by the COVID-19 restrictions. However, the company recovered its revenue in the post-pandemic period.

Moreover, brain-related chronic conditions such as nervous system cancer increased during the pandemic, resulting in the rise of the undiagnosed and untreated patient population.

• In 2022, the National Cancer Institute published a fact sheet on brain and other nervous system cancers. In 2018, the newly reported cases were 6.1% per 1 million people, which reduced to 5.8% in 2019.


• Furthermore, this number increased by 3.9% in 2022 compared to 2019 and is estimated to increase by 1.3% in 2023. Therefore, this shows that reported cases have increased consistently after the pandemic. As the lockdown restrictions were eased, the pending procedures were performed, leading the market growth to its pre-pandemic level in the surgeries conducted. It is anticipated to grow throughout the forecast period 2023-2030.

Key Insights

The report will cover the following key insights:

• Prevalence of Key Neurological Disorders, By Key Countries/Regions, 2022.


• New Product Launches, By Key Players.


• Key Industry Developments - Mergers, Acquisitions & Partnerships.


• Pricing, Key Products / Key Players, Key Regions, 2022.


• Impact of COVID-19 on the Market.

Analysis by Type:

The stereotactic surgery devices market can be segmented by type into Gama Knife, Linear Accelerator, and Proton Beam. In these segments, the gamma knife is likely to dominate the market due to its safety and cost benefits compared to others.

• Leksell Gamma Knife (LGK) is the market's most proven and well-documented stereotactic radiosurgery (SRS) device. It is a safe and cost-efficient treatment option for neurological diseases and brain metastases and an alternative to open surgery and conventional radiotherapy, making it a preferred product and driving its increased use in the market.

Furthermore, the LGK device ensures target delivery at a minimal dose without affecting the surrounding healthy tissue.

• In June 2020, Accuray Incorporated launched a new, fully automated stereotactic device, CyberKnife S7, with a robotic arm for precision and integration. Such launches with advanced technology incorporated will increase the demand for this device leading to market growth.

Regional Analysis:

To gain extensive insights into the market, Request for Customization

In terms of region, North America is likely to dominate the stereotactic surgery devices market. The growth is mainly attributed to an increasing incidence rate of neurological disorders like epilepsy and stroke. The increase in the prevalence of these conditions will surge the demand for their treatment through surgery, driving the demand for these devices. Hence, the increased usage of these products will positively influence the market growth in the forecast period.

• As per the National Institute of Neurological Disorders and Stroke Data published in 2022, about 2.3 million adults in the U.S. live with epilepsy. Every year an estimated 150,000 more people are diagnosed with epilepsy. This increase in the incidence rate of stereotactic surgeries will drive the demand for stereotactic devices.

Key Players Covered

The report will include the profiles of key players such as Elekta, Accuray Incorporated, NORAS MRI products, Mizuho Medical Co. Ltd, inomed Medizintechnik GmbH, Monteris, MITSUBISHI HEAVY INDUSTRIES, LTD., and others.

Segmentation

Key Industry Developments

• March 2023: Elekta and Sinopharm collaborated to improve the access and quality of cancer care in China by adopting radiation therapy in low-tier cities, where around 70% of the population resides.


• February 2023: Elekta strengthened its market position in Asia by acquiring a Thai distributor, Premier Business Inter (PBI).


• September 2022: Monteris Medical enrolled their first patient to initiate their novel REMASTer clinical study on the NeuroBlate system for metastatic brain tumor treatment. The randomized controlled multicenter study is the first to investigate Laser interstitial thermal therapy (LITT) benefits in radiographically recurrent brain metastasis patients.